Literature DB >> 2713864

Motor response following repeated apomorphine administration is reduced in Parkinson's disease.

F Grandas1, J A Obeso.   

Abstract

Ten patients with Parkinson's disease (PD) with motor fluctuations under levodopa treatment were given repeated equal subcutaneous injections of apomorphine [minimal effective dose (MED)] in 1 day. The MED was defined as the dose of apomorphine necessary to induce at least 60% reduction of motor disability for a minimum period of 10 min. MED was found for each patient in previous study days. In eight a subcutaneous infusion of apomorphine was performed on a different day. Four patients with simple fluctuations ("wearing off") showed a progressive reduction of the motor response to apomorphine injections, but three of the four had a stable response (continuous "on") to apomorphine infusion. Six patients with complicated fluctuations also exhibited a decreasing response to successive apomorphine injections and often completely failed to respond to some of the boluses. The response to a subcutaneous infusion of apomorphine was unstable in three of four cases. These findings indicate that a reduction of striatal dopaminergic receptor sensitivity is associated with repeated "pulsatile" apomorphine administration in parkinsonian patients with oscillations of motor performance. It is suggested that altered regulation of dopaminergic receptor sensitivity following pulsatile stimulation with levodopa may be a relevant phenomenon in the pathogenesis of motor fluctuations in PD.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2713864     DOI: 10.1097/00002826-198902000-00002

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  8 in total

Review 1.  Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

Authors:  L Dépatie; S Lal
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

2.  Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms.

Authors:  U Sabatini; O Rascol; P Celsis; G Houin; A Rascol; J P Marc-Vergnes; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

3.  The motor response to sequential apomorphine in parkinsonian fluctuations.

Authors:  A J Hughes; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-04       Impact factor: 10.154

4.  The dopamine receptor agonist apomorphine stabilizes neurotoxic α-synuclein oligomers.

Authors:  Vanderlei de Araujo Lima; Rodrigo Esquinelato; Phelippe Carmo-Gonçalves; Lucas Alex do Nascimento; Hudson Lee; David Eliezer; Luciana Romão; Cristian Follmer
Journal:  FEBS Lett       Date:  2021-12-29       Impact factor: 4.124

Review 5.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

6.  A study of tolerance to apomorphine.

Authors:  J L Montastruc; M E Llau; J M Senard; M A Tran; O Rascol; P Montastruc
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

7.  Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.

Authors:  M M Mouradian; I J Heuser; F Baronti; M Giuffra; K Conant; T L Davis; T N Chase
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-05       Impact factor: 10.154

8.  Induction of tolerance of dopaminergic responses in man.

Authors:  S Lal; J X Thavundayil; N M K Ng Ying Kin; X Dai; G Schwartz; A Montoya
Journal:  J Neural Transm (Vienna)       Date:  2008-05-28       Impact factor: 3.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.